

#### 4. Annemarie Opprecht Parkinson Award 2008

### Curriculum Vitae John Hardy

Ph. D., Professor of Neuroscience, Department of Molecular Neuroscience and Reta Lila Weston Laboratories, Institute of Neurology, University College, Queen Square House, London WC1 3BG, England

**Citizenship:** Dual Citizen of United Kingdom and USA

#### Positions and Employment

1979 - 1983	Postdoctoral Fellow, MCR Neuropathogenesis Unit, Newcastle Upon Tyne, England
1983 - 1984	Assistant Professor, Swedish Brain Bank, Umea, Sweden
1984 - 1992	Assistant, then (1989) Associate Professor, Department of Biochemistry and Molecular Genetics, St. Mary's Hospital Medical School, Imperial College, London.
1992 - 1996	Pfeiffer Professor in Alzheimer's Research, Departments of Psychiatry, Pharmacology and Neurology, University of South Florida, Tampa, Florida
1996 - 2001	Director of Neuroscience and Consultant (Professor), Mayo Clinic Jacksonville
2001 - 2004	Visiting Scientist, Mayo Clinic Jacksonville
2001 - 2007	Tenured Senior Investigator and Chief of Laboratory of Neurogenetics
2001 - Present	Professor of Neuroscience, University College, London

#### Honors

1986	Cottrell Fellowship (UK) for Research into Alzheimer's Disease
1991	Peter Debye Prize (Belgium), for Research into Alzheimer's Disease
1992	IPSEN Prize (France: shared) research into Alzheimer's Disease
1993	Potamkin Prize (USA: shared) for Alzheimer's Disease Research
1995	Met Life Prize (USA: shared) for Alzheimer's Disease Research
1995	Allied Signal Prize (USA) for Progress in Aging Research
2002	Kaul Prize for Alzheimer Research
2008	Elected Fellow of the Academy of Medical Science
2008	Honorary MD, Umea University, Sweden

## **Publications (from 500)**

**Van Broeckhoven C**, et al. Amyloid  $\beta$  protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). *Science* 1990; 248: 1120.

**St. George-Hyslop PH**, et al. Genetic linkage studies suggest that Alzheimer's disease is not a single homogenous disorder. *Nature* 1990;347:194.

**Goate AM**, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* 1991;349:704.

**Chartier-Harlin MC**,. Early onset Alzheimer's disease caused by mutations at codon 717 of the  $\beta$ -amyloid precursor protein gene. *Nature* 1991;353:844.

**Hardy JA**, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science* 1992;256:184.

**Scheuner D**, et al. Secreted amyloid  $\beta$ -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nature Med* 1996 Aug;2(8):864.

**Duff K**, et al. *Nature* 1996;383:710.

**Holcomb L** et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. *Nature Med* 1998 Jan;4:97.

**Crook R**, A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. *Nature Med* 1998;4:452.

**Hutton M** et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* 1998;393:702.

**Lewis J**, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. *Nature Genet* 2000;25:402.

**Myers A**, et al. Susceptibility locus for Alzheimer's disease on chromosome 10. *Science* 290 (2000) 2304.

**Morgan D**, et al. A $\beta$  peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. *Nature* 2000 408:982.

**Lewis J**, et al.. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. *Science* 2001;293:1487.

**Hardy J**, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 2002;297:353.

**Singleton A**, et al.  $\alpha$ -Synuclein locus triplication causes Parkinson's disease. *Science* 2003;302:841.

**McGowan E**, et al. A $\beta$ 42 is essential for parenchymal and vascular amyloid deposition in mice. *Neuron* 2005 ;47:191.

**Fung HC, Scholz S, Matarin M, Simon-Sanchez J, Hernandez D, Britton A, Gibbs JR, Langefeld C, Stiegert ML, Schymick J, Okun MS, Mandel RJ, Fernandez HH, Foote KD, Rodriguez RL, Peckham E, De Vrieze FW, Gwinn-Hardy K, Hardy JA, Singleton A. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. *Lancet Neurol.* 2006 Nov;5(11):911-916.**

**Myers AJ**, et al. *Nature Genetics* (in press).

**Jakobsson M**, et al. *Nature*. 2008;451:998 **Zody MC**, et al. *Nat Genet.* 2008 (in press).